-serum electrolytes: Na+, K+, CI-, HC03- 
-fasting blood glucose 
-BUN 
-uric acid 
-total bilirubin 
-alkaline phosphatase (if >2X upper limit of normal, then GGTP) 
-alanine aminotransferase (ALT) 
-aspirate aminotransferase (AST) 
-lactate dehydrogenase (LDH) and, if elevated, LDH isoenzymes 
-calcium, albumin, total protein 
-quantitative immunoglobulins 
-Hepatitis B and C serologic screens 
-blood cultures for Mycobacterium avium- intracellulare 
-serum cryptococcal antigen 
-Lymphocyte Profile (to include but not limited to: cellular phenotype of 
peripheral blood by FACS analysis, including CD4+ and CD8+ counts 
and percentages, in vitro lymphocyte proliferative assays including 
responses to mitogens [PHA, PWM, Con-A], soluble antigens [Diptheria, 
Tetanus, Candida albicans], alloantigen, and anti-CD3 ± IL2; and 
determination of cytotoxic cell function 
-HIV PCR (donor only) 
-HIV ELISA with confirmatory Western blot 
-serum p24 antigen 
-quantitative HIV cultures of plasma 
-p2 microglobulin 
-Quantitative DNA polymerase chain reaction (PCR) of DNA extracted 
from PBMC utilizing primers specific for the neoR gene 
-PPD and tetanus toxoid control 
-Tetanus toxoid booster 
-urinalysis including microscopic 
-chest x-ray within 2 weeks of entry 
-12-lead electrocardiogram within 2 weeks of entry 
All patients will have their blood drawn either in the outpatient clinic, day 
hospital, inpatient units, or in the Clinical Center phlebotomy service area. 
5.5.2 Efficacy Evaluations 
This is a Phase I/ll trial primarily directed toward assessing safety and 
toxicity of administering genetically marked syngeneic peripheral 
blood lymphocytes. Preliminary efficacy data will also be obtained 
Recombinant DNA Research, Volume 16 
[305] 
